Skip to main content
Signal8
Launch Terminal

Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc.

NASDAQ:CLRBHealthcare
-1.23%$1.21
AH$1.21+0.00%vs close
Mkt Cap$11.39M
Float9.4M
O/S9.45M
Vol
$ Vol
RVOL
Inst Own34.5%
Earnings
Dilution
Cellectar Biosciences, Inc. logoNASDAQ:CLRB$1.21-1.23%
Upcoming Catalysts
Phase Distribution
14 lead-sponsored trials·4 active·7 completed
Phase 17
Phase 25
Phase 32
(4 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

    Paclitaxel, NOV-002

    Non Small Cell Lung Cancer

    Enrollment
    903
    Start
    Nov 2006
    Primary Completion
    Jan 2010
    Completion
    Feb 2010
    NCT00347412
  • Phase 3
    Not yet recruiting

    Evaluation of Iopofosine I 131 vs. R-CD in WM Patients

    Iopofosine I 131, Rituximab (active comparator)

    Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia +3

    Enrollment
    219
    Start
    Dec 2026est.
    Primary Completion
    Jan 2032est.
    Completion
    Jan 2035est.
    NCT07766421
  • Phase 2
    Completed

    Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer

    NOV-002, Carboplatin

    Ovarian Cancer

    Enrollment
    15
    Start
    Jul 2006
    Primary Completion
    May 2008
    Completion
    Jun 2008
    NCT00345540
  • Phase 2
    Completed

    A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy

    NOV-205

    Hepatitis C

    Enrollment
    22
    Start
    Mar 2010
    Primary Completion
    Dec 2010
    Completion
    Dec 2010
    NCT01058512
  • Phase 2
    Withdrawn

    Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma

    I-131-CLR1404 Injection

    Glioma

    Enrollment
    0
    Start
    May 2014
    Primary Completion
    Jun 2014est.
    Completion
    Jan 2015est.
    NCT01778088
  • Phase 2
    Terminated

    Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma

    I-124-CLR1404

    Glioblastoma

    Enrollment
    7
    Start
    Feb 2014
    Primary Completion
    Sep 2015est.
    Completion
    Dec 2015est.
    NCT01898273
  • Phase 2
    Active, not recruiting

    Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

    Iopofosine I 131 single dose, Iopofosine I 131 multiple dose

    Waldenstrom Macroglobulinemia, Multiple Myeloma +7

    Enrollment
    120
    Start
    Jul 2017
    Primary Completion
    Jun 2026est.
    Completion
    Dec 2027est.
    NCT02952508
  • Phase 1
    Completed

    Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy

    NOV-205

    Hepatitis C

    Enrollment
    30
    Start
    Aug 2006
    Primary Completion
    -
    Completion
    Dec 2007
    NCT00372983
  • Phase 1
    Completed

    Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors

    I-131-CLR1404

    Solid Tumors

    Enrollment
    9
    Start
    Jun 2009
    Primary Completion
    Feb 2010
    Completion
    Feb 2010
    NCT00925275
  • Phase 1
    Completed

    Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

    I-131-CLR1404

    Cancer

    Enrollment
    12
    Start
    Dec 2011
    Primary Completion
    Nov 2013
    Completion
    Jan 2014
    NCT01495663
  • Phase 1
    Completed

    Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

    I-131-CLR1404, dexamethasone

    Multiple Myeloma

    Enrollment
    31
    Start
    Feb 2015
    Primary Completion
    Dec 2020
    Completion
    Aug 2022
    NCT02278315
  • Phase 1
    Active, not recruiting

    Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

    CLR 131

    Pediatric Solid Tumor, Pediatric Lymphoma +6

    Enrollment
    30
    Start
    Apr 2019
    Primary Completion
    Jun 2027est.
    Completion
    Dec 2027est.
    NCT03478462
  • Phase 1
    Active, not recruiting

    Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

    CLR 131

    High-Grade Glioma

    Enrollment
    50
    Start
    Oct 2023
    Primary Completion
    Jun 2027est.
    Completion
    Dec 2027est.
    NCT05610891
  • Phase 1
    Recruiting

    Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

    Iopofosine I 131, CLR 125

    Breast Cancer

    Enrollment
    60
    Start
    Dec 2025
    Primary Completion
    Feb 2028est.
    Completion
    Jul 2029est.
    NCT07311993
Search ClinicalTrials.gov for “Cellectar Biosciences”